ANCI signs agreement with Annapolis for healthcare solution

NewsGuard 100/100 Score

American CareSource Holdings, Inc. (NASDAQ: ANCI), the nation's leading ancillary health care network services company, announced today that it has signed and implemented an agreement with Annapolis, Maryland-based Self Funding Administrators Corporation ("SFA"), a third party administrator ("TPA") representing an additional 30,000 covered lives.

David S. Boone, Chief Executive Officer of American CareSource ("ACS") noted, "The addition of SFA to our client portfolio has provided us an opportunity to become an integral part of SFA's affordable healthcare solution. The SFA suite of services can all benefit from access to ACS' more than 36,000 quality provider locations."

Chris Hutchinson, President of SFA stated, "We are equally pleased to offer our clients the benefits of the ACS provider network. In today's changing world of healthcare, our goal is to design and manage employee benefit plans that are not only cost effective for the employer, but also meet the ever-changing needs of the employee and his family. ACS' network customization allows us to maximize provider access by all employees."

Source:

American CareSource Holdings, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI in healthcare shows promise in trials but needs real-world testing to ensure effectiveness